# Neoadjuvant Treatment for Advanced Rectal Carcinoma

> **NCT02551237** · PHASE3 · COMPLETED · sponsor: **UNICANCER** · enrollment: 103 (actual)

## Conditions studied

- Rectal Carcinoma

## Interventions

- **RADIATION:** 50 Gy
- **DRUG:** Capecitabine
- **RADIATION:** 25 Gy

## Key facts

- **NCT ID:** NCT02551237
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-07
- **Primary completion:** 2020-08-29
- **Final completion:** 2022-06
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02551237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02551237, "Neoadjuvant Treatment for Advanced Rectal Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02551237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*